Role and mechanism of Roux-en-Y gastric bypass in the treatment of diabetic urinary bladder hyperactivity by reducing TRPV1 and P2X3

Table 1 List of antibodies

Antibody	Source	Catalogue number	Dilution
TRPV1	Bioss	bs-23926R	1:800 (Wb); 1:500 (IHC, IF)
P2X3	Santa Cruz	sc-390572	1:1000 (Wb); 1:500 (IHC, IF)
NF-κB	ABclonal	A18210	1:1000 (Wb)
IL-1β	Affinity	AF5103	1:1000 (Wb)
IL-6	Affinity	DF6087	1:1000 (Wb)
TNF-α	ABclonal	A0277	1:1000 (Wb)
p-mTOR	Cell signaling technology	2971	1:1000 (Wb)
mTOR	Cell signaling technology	2983	1:1000 (Wb)
p-AMPK	Cell signaling technology	2535	1:1000 (Wb)
AMPK	Cell signaling technology	2532	1:1000 (Wb)
GAPDH	Wanleibio	WL01114	1:2000 (Wb)
β-actin	Santa Cruz	sc-47778	1:2000 (Wb)

AMPK: AMP-activated protein kinase; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; IF: Immunofluorescence; IHC: Immunohistochemistry; IL: Interleukin; mTOR: mammalian target of rapamycin; NF-κB: Nuclear factor kappa B; P2X3: Purinergic receptor P2X3; TNF-α: Tumor necrosis factor alpha; TRPV1: transient receptor potential vanilloid type 1; Wb: Western blot.